Ipca Laboratories Ltd. Transfers Monoclonal Antibody Biosimilar Technology to Biosimilar Sciences PR LLC, Creating U.S. Jobs and Securing Supply Chain
Ipca Laboratories Ltd. and Biosimilar Sciences PR LLC (BSS) have announced a definitive Technology Transfer and Joint Development Agreement. This agreement will shift late-stage development, clinical manufacture, and commercial supply of a next generation anti-cancer / anti-inflammatory monoclonal antibody biosimilar from Ipca to BSS's 200,000 square feet sterile campus in Aguadilla, Puerto Rico. This deal is expected to create hundreds of high-paying jobs in Puerto Rico, secure the supply chain, and target 2028/29 FDA approval. The transaction also stitches together an integrated, end-to-end biosimilar company, delivering Made-in-America quality at globally competitive prices. The India-Puerto Rico partnership is the economic engine that turns the mission of affordable medicines for the world into reality.
Key Highlights
- Ipca to transfer technology of a monoclonal antibody biosimilar to Biosimilar Sciences PR LLC, USA.
- The biosimilar is an anti-cancer / anti-inflammatory monoclonal antibody with a current US market of more than USD 4 Billion and expected to grow at 12% AGR.
- The technology transfer is expected to create hundreds of high-paying jobs in Puerto Rico and secure the supply chain.
- The deal targets 2028/29 FDA approval and stitches together an integrated, end-to-end biosimilar company.
- The India-Puerto Rico partnership is the economic engine for delivering Made-in-America quality at globally competitive prices.